Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with Ribavirin, mycophenolate motelil (CellCept®), amantadine, or amantadine plus ribavirin in patients that relapsed on rebetronTM therapy: A preliminary report of a randomized, multicenter efficacy and safety study
Publication/Presentation Date
4-2001
Volume
120
Issue
5
First Page
384
Last Page
384
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS